Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
Doximity: Elite Margins, AI Growth, And An Attractive Multiple
Doximity's Q2 results show record engagement and accelerating adoption of AI workflow tools, signaling deeper physician reliance on the platform. Revenue quality is improving as pharma clients shift from one-off ad buys to longer-term integrated programs. Doximity has a strong Rule-of-50 profile with high margins and $890m cash but no debt.
Here's Why Doximity (DOCS) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Dr Martens drops despite results in line with forecasts
Dr Martens PLC (LSE:DOCS) shares stomped almost 7% lower to 76p after the bootmaker reported first half results in line with market expectations, saying it expects to offset the full-year effect of US tariffs. Revenue for the 26 weeks to 28 September came in at £322 million, down 0.8% versus a year ago, or up 0.8% on a constant currency basis.
Why Doximity (DOCS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Doximity Stock Down Despite Q2 Earnings Beat, Revenues Up Y/Y
DOCS Q2 results benefit from the rise in AI-driven engagement. However, the stock plunges nearly 9% in pre-market trading.
Doximity, Inc. (DOCS) Q2 2026 Earnings Call Transcript
Doximity, Inc. ( DOCS ) Q2 2026 Earnings Call November 6, 2025 5:00 PM EST Company Participants Perry Gold - Head of Investor Relations Jeffrey Tangney - Co-Founder, CEO & Chairperson Anna Bryson - Chief Financial Officer Conference Call Participants Brian Peterson - Raymond James & Associates, Inc., Research Division Michael Cherny - Leerink Partners LLC, Research Division Allen Lutz - BofA Securities, Research Division Ryan Daniels - William Blair & Company L.L.C., Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Ryan MacDonald - Needham & Company, LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Craig Hettenbach - Morgan Stanley, Research Division Derek Gross - Piper Sandler & Co., Research Division Brian Tanquilut - Jefferies LLC, Research Division Stanislav Berenshteyn - Wells Fargo Securities, LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division David Roman - Goldman Sachs Group, Inc., Research Division Eric Percher - Nephron Research LLC Jenny Shen - BTIG, LLC, Research Division Jenny Cao - Truist Securities, Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by.
Compared to Estimates, Doximity (DOCS) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Doximity (DOCS) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates
Doximity (DOCS) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.3 per share a year ago.
Doximity (DOCS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Doximity (DOCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Doximity (DOCS) Beat Estimates Again in Its Next Earnings Report?
Doximity (DOCS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Buy These 5 Health and Fitness Stocks for a Stable Portfolio in Q4
DOCS, PLNT, UNFI, PTON and PFGC are five health and fitness stocks with growth potential, diversified revenue and resilient demand.
